These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 31512006)
1. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006 [TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762 [TBL] [Abstract][Full Text] [Related]
3. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231 [TBL] [Abstract][Full Text] [Related]
4. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706 [TBL] [Abstract][Full Text] [Related]
5. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714 [TBL] [Abstract][Full Text] [Related]
6. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study. Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491 [TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096 [TBL] [Abstract][Full Text] [Related]
8. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K Urol Oncol; 2020 May; 38(5):526-532. PubMed ID: 31864934 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525 [TBL] [Abstract][Full Text] [Related]
10. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695 [TBL] [Abstract][Full Text] [Related]
11. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479 [TBL] [Abstract][Full Text] [Related]
13. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991 [TBL] [Abstract][Full Text] [Related]
14. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma. Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929 [TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390 [TBL] [Abstract][Full Text] [Related]
16. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma. Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209 [TBL] [Abstract][Full Text] [Related]
19. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493 [TBL] [Abstract][Full Text] [Related]
20. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]